tbuckley/cabot-search huggingface dataset:
Journal of Neurochemistry, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arboviral Disease—United States, 1994
Journal: JAMA (1995)

Arboviruses are mosquitoborne and tickborne agents that persist in nature in complex cycles involving birds and mammals, including humans. Characteristics of arboviral infection include fever, headache, encephalitis, and sometimes death. In 1994, health departments in 20 states reported 100 presumptive or confirmed human cases of arboviral disease to CDC. Of these, 76 were California (CAL) serogroup encephalitis; 20, St. Louis encephalitis (SLE); two, western equine encephalomyelitis (WEE); one, eastern equine encephalomyelitis (EEE); and one, Powassan encephalitis (POW). This report summarizes information about arboviral disease in the United States during 1994.
INFECTION, TISSUE TEMPERATURES, AND DRESSINGS
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
Authors: Gary K. Schwartz, Douglas Adkins, Rebecca Suk Heist, Maura Abbott, Stephanie L. Barber, Richard C. Chao, Saskia T.C. Neuteboom, Isan Chen, James Christensen, Todd Michael Bauer
Journal: Journal of Clinical Oncology (2015)

TPS2621 Background: MGCD516, is an orally-available, potent small molecule inhibitor of a closely related family of RTKs including RET, TRK family, DDR2, MET, Axl family, KIT, as well as VEGFR and PDGFR family members. RTKs inhibited by MGCD516 are genetically altered in a variety of cancers, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), functioning as oncogenic drivers promoting cancer development and progression. Alterations in these RTKs have also been implicated in tumor resistance mechanisms. MGCD516 has demonstrated broad antitumor activity including demonstration of tumor regression in preclinical models harboring genetic dysregulation of MGCD516 targets including MET amplification, METex14del, RET rearrangement and CHR4q12 amplification. Methods: This first-in-human, open label Phase 1/1b study is designed to evaluate the safety, pharmacokinetics, metabolism, pharmacodynamics and clinical activity of MGCD516 in patients with advanced solid tumors. Phase 1 is the dose escalation phase and uses the modified toxicity probability interval (mTPI) method to determine the MTD /Recommended Phase 1b Dose. Phase 1b is the expansion phase in which MGCD516 will be evaluated in patients with NSCLC, HNSCC, or any other solid tumor type harboring specific MGCD516 RTK target mutations of interest. Phase 1 and 1b are each anticipated to enroll 60 patients. Phase 1 enrollment started in September 2014, with patients receiving continuous daily dosing (QD) of 10mg MGCD516 in cycles of 21 days. Cohort 1 and Cohort 2 (QD 20mg) have been completed without DLTs and enrollment to Cohort 3 (QD 40mg) started in January 2015. Pharmacokinetics is evaluated after single and repeated administration. Pharmacodynamic biomarkers, including soluble (s)MET, sVEGFR2 and VEGFA will be explored in plasma samples for prognostic potential and possible relationship with clinical outcome. Clinical trial information: NCT02219711.
SPONTANEOUS GANGRENE IN CHILD, DUE TO DISEASE OF VESSEL WALL.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
(40) Amiodarone-induced photosensitivity and pigmentation
Authors: C. B. Zachary, G. Storey, D. Holt, D. Slater, J. Hawk, W. J. McKenna, D. M. MacDonald
Journal: British Journal of Dermatology (1983)

Journal Article (40) Amiodarone‐induced photosensitivity and pigmentation Get access C. B. Zachary, C. B. Zachary Guy's, Royal Hallamshire, St John's and Hammersmith Hospitals Search for other works by this author on: Oxford Academic Google Scholar G. Storey, G. Storey Guy's, Royal Hallamshire, St John's and Hammersmith Hospitals Search for other works by this author on: Oxford Academic Google Scholar D. Holt, D. Holt Guy's, Royal Hallamshire, St John's and Hammersmith Hospitals Search for other works by this author on: Oxford Academic Google Scholar D. Slater, D. Slater Guy's, Royal Hallamshire, St John's and Hammersmith Hospitals Search for other works by this author on: Oxford Academic Google Scholar J. Hawk, J. Hawk Guy's, Royal Hallamshire, St John's and Hammersmith Hospitals Search for other works by this author on: Oxford Academic Google Scholar W. J. McKenna, W. J. McKenna Guy's, Royal Hallamshire, St John's and Hammersmith Hospitals Search for other works by this author on: Oxford Academic Google Scholar D. M. MacDonald D. M. MacDonald Guy's, Royal Hallamshire, St John's and Hammersmith Hospitals Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 109, Issue s24, 1 July 1983, Page 96, https://doi.org/10.1111/j.1365-2133.1983.tb11647.x Published: 01 July 1983
PHTHISIS AND TUBERCULOSIS.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alcohol and Risk for Heart Failure
Journal: Annals of Internal Medicine (2002)

Summaries for Patients5 February 2002Alcohol and Risk for Heart FailureSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-3-200202050-00001 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Drinking alcohol regularly and heavily for many years can weaken the muscle walls of the heart. The weakened muscles then stretch, which causes the heart to become larger. A large, weakened heart cannot pump blood through the body normally. Such symptoms as fatigue, shortness of breath, and leg swelling result. Doctors call this problem alcohol-related heart failure, or alcoholic cardiomyopathy. Drinking small to moderate amounts of alcohol, on the other hand, may help prevent heart attacks. Heart attacks occur when blood flow through the arteries to the heart ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Alcohol Consumption and Risk for Congestive Heart Failure in the Framingham Heart Study.” It is in the 5 February 2002 issue of Annals of Internal Medicine (volume 136, pages 181-191). The authors are CR Walsh, MG Larson, JC Evans, L Djousse, RC Ellison, RS Vasan, and D Levy.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAlcohol Consumption and Risk for Congestive Heart Failure in the Framingham Heart Study Craig R. Walsh , Martin G. Larson , Jane C. Evans , Luc Djousse , R. Curtis Ellison , Ramachandran S. Vasan , and Daniel Levy Metrics 5 February 2002Volume 136, Issue 3Page: I-16KeywordsAlcoholsHeartHeart failureLongitudinal studiesMusclesMyocardial infarctionMyocardiumPrimary hypertensionRisk managementStable coronary artery disease ePublished: 5 February 2002 Issue Published: 5 February 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Upper body pain: possible tipoff to Pancoast tumor
Authors: T. Ziporyn
Journal: JAMA (1981)

The bone scans and chest and spine films may say no, but the pain says yes. In patients with Pancoast (superior pulmonary sulcus) tumors, at least, the most reliable indicator of initial, recurrent, or progressive disease may be as simple as pain in the shoulder, chest, or arm. Pancoast tumors represent 3% to 4% of all lung cancers and often can be detected only by an apical lordotic chest film, which is not routinely requested. Moreover, because of the tumors' proximity to the brachial plexus and the spinal column, one of their major neurological complications, epidural spinal cord compression (ESCC), may be missed. According to Ronald M. Kanner, MD, initial radiation therapy for the tumor may include the vertebral body and reduce osteoblastic activity, or the tumor may grow into the intervertebral foramen without producing bone changes. Thus, the ability of bone scans to detect ESCC is impeded. Myelography is
<i>Book on the Physician Himself, and Things that Concern His Reputation and Success</i>. By D. W. Cathell, M. D. New Tenth Edition (Author's Last Revision.) Thoroughly revised, enlarged, and rewritten. In one handsome Royal Octavo volume. 348 pages. Bound in Extra Cloth. Price, post-paid, $2.00, net. Philadelphia: The F. A. Davis Co., Publishers, 1231 Filbert Street
Authors: A. M.
Journal: American Journal of Psychiatry (1892)
Rheumatic fever in the adult
Authors: I. J. Adatto
Journal: JAMA (1965)

The clinical manifestations of acute rheumatic fever were evaluated in a study of 35 adult patients. Migratory polyarthritis occurred in all but one. None had chorea, erythema marginatum, or subcutaneous nodules. Carditis occurred in eight, manifested by pericarditis in four and by development of new significant murmurs in four. Two patients died during their acute attacks, and nine exhibited new valve damage on follow-up. The results of the study indicate that rheumatic fever represents a continuous spectrum from childhood to adulthood, in which the incidence of carditis, though diminishing, remains significant. In addition, cardiac involvement may occur de novo in the adult, resulting in permanent damage or even death. This would have important implications regarding penicillin prophylaxis.
HEMORRHAGE AS A FORM OF ASPHYXIA
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
31P magnetic resonance spectroscopy of the liver: Correlation with standardized serum, clinical, and histological changes in diffuse liver disease
Authors: Hester N. van Wassenaer-Van Hall, Jeroen van der Grond, Jan van Hattum, Carole Kooijman, Tjaard U. Hoogenraad, Willem P. Th. M. Mali
Journal: Hepatology (1995)

The goal of this study was to analyze the possibilities of 31 P MR spectroscopy to detect abnormal hepatic histological changes in patients with diffuse liver disease. 31 P MR spectroscopy was performed, on a 1.5 T whole-body spectrometer using an image guided localization technique (ISIS), on 38 patients with various diffuse liver diseases, who all underwent histological and serum analysis, and 22 healthy volunteers. Phosphomonoester expressed as a fraction of total phosphorus (PME/P) showed a correlation with abnormal serum aspartate transaminase (AST), histological intralobular degeneration/focal necrosis, portal inflammation, and piecemeal necrosis. We found a lower correlation for PME/P with fibrosis. It was not possible to differentiate between fibrosis and cirrhosis. In summary, 31 P MR spectroscopy is a technique to detect intralobular degeneration, inflammation and necrosis and to a less extent fibrosis. No diagnostic value was found with respect to steatosis and cholangitis. Furthermore, 31 P MR spectroscopy is a poor method for classifying patients into diagnostic categories. (Hepatology 1995;21:443-449.)
Mitral Valve Replacement or Repair After Previous Coronary Artery Bypass Grafting
Authors: Uzi Izhar, Richard C. Daly, Joseph A. Dearani, Thomas A. Orszulak, Hartzell V. Schaff, Charles J. Mullany
Journal: Circulation (1999)

Background —Patients who have had previous CABG may subsequently develop significant mitral valve (MV) dysfunction that requires surgical intervention. Methods and Results —We reviewed 80 consecutive patients who had had previous CABG and who underwent MV surgery between January 1972 and March 1997. Forty-seven (59%) had initial CABG elsewhere, and 5 had had previous CABG twice. The mean interval between the previous CABG and the MV surgery was 6.3 years (range, 4.4 months to −17 years). At least 15 patients had grade 1/4 to 2/4 mitral regurgitation at initial CABG. The study group included 59 men and 21 women, with a mean study group age of 65.5 years. Ninety-four percent had symptoms of congestive heart failure, 60% had angina, 96% were in NYHA class III to IV, and 37% had an ejection fraction (EF) &lt;50%. Origin of the MV disease was ischemic in 33 patients, myxomatous in 19, combined ischemic and myxomatous in 16, rheumatic in 5, infective in 3, and unknown in 4. MV repair was performed in 46 patients (58%) and MV replacement (MVR) in 34. Concomitant repeat CABG was performed in 38 (48%) patients. In-hospital mortality was 7 of 80 (8.8%); no early death occurred among patients with myxomatous disease. EF &lt;50% was the only significant predictor of early mortality. Overall 1-, 5-, and 10-year survival was 83.8%, 55.6%, and 34.4% respectively. Predictors of late cardiac death were preoperative NYHA class IV ( P =0.0006), urgent or emergency operation ( P &lt;0.0001), use of intra-aortic balloon pump ( P =0.002), and EF &lt;50% ( P =0.01). Seven patients had an additional reoperation: 4 received CABG, 2 MVR, and 2 MV repair. Conclusions —Ischemic, myxomatous, rheumatic, or infective MV dysfunction may develop subsequently after CABG. MVR or MV repair after previous CABG is associated with an acceptably low operative risk and good relief of symptoms. Left ventricular function is strongly correlated with both hospital and late mortality. Surgery should be done before LV dysfunction develops.
Allergen and Endotoxin Exposure, Infection, and Breastfeeding in Early Life, and Recurrent Wheezing in Infants: 18-month Follow-up of a Cohort Study
Authors: V.E.V. Rullo, D. Solé, V. Valente, C. Nakamura, A.S. Zampolo, L.K. Arruda, R.C. Cardoso, F.J. Nóbrega, C.K. Naspitz
Journal: Journal of Allergy and Clinical Immunology (2007)
Preliminary results of a multicenter phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer
Authors: K. Schuette, M. Moehler, E. Kettner, S. Al-Batran, S. Hegewisch-Becker, C. Steffens, A. Pustowka, E. Goekkurt, G. Ehninger, J. Stoehlmacher
Journal: Journal of Clinical Oncology (2009)

e15622 Background: There are no standard chemotherapeutic regimens for incurable biliary adenocarcinomas. Monotherapies with gemcitabine or FU/LV achieve occasional responses and a median overall survival of about 6 months. By blocking PDGFR a decreased intrastromal pressure may increase therapy effects of chemotherapy. The combination of imatinib and FU/LV has been shown to be safe and feasible in a previous Phase I trial. This multicenter phase II trial was designed to investigate the disease control rate (DCR) of FU/LV and imatinib. Methods: Eligibility criteria included unresectable or metastatic measurable biliary tract cancer (BTC)/gallbladder cancer (GBC), performance status &lt; 2, adequate organ function and no clinically significant cardiovascular disease. Enrolment of 44 chemonaive patients (pts.) was planned. Pts. received LV 200 mg/m2 followed by FU 2000 mg/m2 as a 24-hour infusion on days 1 and 2 combined with 600mg imatinib on days -4 to 4 (8 days). Cycles were repeated every 2 weeks up to 12 cycles. Radiological assessments were performed every 4 cycles. Results: 41 pts (19 GBC; 22 BTC) were enrolled in this phase II study since May 2007. Median age was 62 years (range 33–77), male/female=24/17, ECOG 0/1/2=13/23/5. 35 pts. showed metastatic disease at baseline. Treatment was well tolerated. Treatment related grade 3/4 toxicities included (number of pts): diarrhea (2), edema (1), neutropenia (2), nausea (2), transient SGPT elevation (4). The DCR of 26 pts. available for response assessment at time of analysis 1 was 58% (15 pts) (1 CR, 1 PR,13 SD of at least 4 cycles). 11 pts. showed progressive disease (PD) per RECIST criteria. 3 pts. had disease stabilization after 12 cycles and continue on treatment. We present these preliminary data as they represent a large patient number in this entity and response data are promising. Conclusions: This preliminary analysis suggests that the combination of FU/LV and imatinib can be safely administrated in pts. with GBC/BTC. Early evidence of antitumor activity was seen with some pts. achieving long term stabilization of the disease. [Table: see text]
How to be a really good bully
Authors: Anita Houghton
Journal: BMJ (2005)

Anita Houghton gives some tongue in cheek tips on how to be an effective bully and get away with it I've heard many stories of bullying from the lips of able and sometimes senior men and women within the medical profession, who, by the time they see me, have usually been reduced to nervous wrecks. So I feel well qualified to guide aspiring bullies to the kinds of skills and behaviours that are required to be effective… and get away with it. Remember, the aim of the bully is to gain power through fear. As long as you're careful while attaining power, once you have it you can look forward to doing more or less what you like. Here's how it's done. This is essential. People have low tolerance for incompetent bullies but infinite tolerance for bullies who shift waiting lists, bring in money, and generate heart-wrenching letters of gratitude from patients whose lives they've saved. You can try being a bully while being lousy at your job, but consider, do you really want to draw attention to yourself? If you do, it is only a matter of time before somebody decides that your appalling behaviour is just the excuse they were looking for to get rid of you. This is another important piece of your armament. Part of surviving as a bully is having a large number of people in senior positions who think you are a thoroughly engaging sort of chap or chapess. Not only will these people greet any reports of your exploits with snorts of disbelief, but they will be indispensable if anyone is foolish enough to make a formal complaint. ### Top tips for the aspiring bully